Compare Novagold Resources Inc. (NG) vs Novavax Inc (NVAX) Price & Performance

NovaGold Resources (NG) trades at $6.63, down 1.49% today, as the company navigates its development phase for the Donlin Gold project. The stock shows mixed earnings performance with recent quarterly losses but beats expectations in two of the last four quarters. Financials reveal negative profitability metrics with ROE at -32.81% and net income of -$94.66M for 2025, though cash flow remains positive due to financing activities. Recent news highlights the company's move to acquire full ownership of Donlin Gold, a major Alaska gold project.

The outlook for NG hinges on successful development of Donlin Gold, with 100% analyst buy ratings signaling strong Wall Street confidence. However, significant execution risks exist given negative earnings and substantial capital requirements. Investors face volatility from gold price fluctuations and project development timelines, making this suitable for those with high risk tolerance seeking exposure to a major gold development story.

Novavax (NVAX) trades at $12.64, down slightly by 0.16% on the day. The stock shows a bullish technical signal with strong moving average and oscillator support. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of -$0.32 surpassing the -$0.38 estimate. The company is transitioning its business model toward a partnership-driven approach centered on its Matrix-M adjuvant technology, with recent regulatory approvals for its updated COVID-19 vaccine in major markets.

The outlook is mixed with strong analyst buy ratings (73.9%) and recent business developments providing catalysts, but significant financial risks remain including negative cash flows, high debt levels, and inconsistent profitability. Investment opportunity exists in the partnership strategy execution, while risks include execution challenges and competitive pressures in the vaccine market.